S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:VCNX

Vaccinex (VCNX) Stock Price, News & Analysis

$7.41
-0.04 (-0.54%)
(As of 03/28/2024 ET)
Today's Range
$7.29
$8.11
50-Day Range
$7.41
$12.25
52-Week Range
$7.16
$100.80
Volume
18,505 shs
Average Volume
10,810 shs
Market Capitalization
$6.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VCNX stock logo

About Vaccinex Stock (NASDAQ:VCNX)

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.

VCNX Stock Price History

VCNX Stock News Headlines

Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Vaccinex Inc VCNX
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Vaccinex Announces 1-For-14 Reverse Stock Split
Why Vaccinex (VCNX) Stock Is Trading Lower
Vaccinex, Inc. Announces Reverse Stock Split
Why Vaccinex (VCNX) Stock Is Popping Off
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
Why Is Vaccinex (VCNX) Stock Up 26% Today?
Vaccinex Shares Slide Premarket After Stock Offering
Vaccinex Announces Pricing of $9.6 Million Public Offering
See More Headlines
Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/29/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VCNX
Employees
38
Year Founded
N/A

Profitability

Net Income
$-19,820,000.00
Pretax Margin
-2,768.80%

Debt

Sales & Book Value

Annual Sales
$280,000.00
Book Value
$21.86 per share

Miscellaneous

Free Float
434,000
Market Cap
$6.59 million
Optionable
Optionable
Beta
0.76
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Maurice Zauderer Ph.D. (Age 78)
    Co-Founder, CEO, President & Director
    Comp: $400.7k
  • Dr. Elizabeth E. Evans Ph.D. (Age 52)
    COO and Senior VP of Discovery & Translational Medicine
    Comp: $255.46k
  • Dr. Ernest S. Smith Ph.D. (Age 52)
    Senior VP of Research & Chief Scientific Officer
    Comp: $284.02k
  • Mr. Scott E. Royer C.F.A. (Age 50)
    M.B.A., Chief Financial Officer
    Comp: $242.15k
  • Dr. John E. Leonard Ph.D. (Age 77)
    Senior Vice President of Development

VCNX Stock Analysis - Frequently Asked Questions

How have VCNX shares performed in 2024?

Vaccinex's stock was trading at $9.3072 at the beginning of the year. Since then, VCNX stock has decreased by 20.4% and is now trading at $7.41.
View the best growth stocks for 2024 here
.

Are investors shorting Vaccinex?

Vaccinex saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 8,800 shares, a drop of 40.5% from the February 29th total of 14,800 shares. Based on an average trading volume of 11,100 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.5% of the company's shares are sold short.
View Vaccinex's Short Interest
.

When is Vaccinex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our VCNX earnings forecast
.

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) issued its quarterly earnings data on Monday, November, 8th. The company reported ($35.70) earnings per share for the quarter, beating the consensus estimate of ($60.90) by $25.20. The firm earned $0.05 million during the quarter.

When did Vaccinex's stock split?

Shares of Vaccinex reverse split before market open on Tuesday, February 20th 2024. The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

When did Vaccinex IPO?

Vaccinex (VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Who are Vaccinex's major shareholders?

Vaccinex's stock is owned by many different institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (6.54%), Worth Venture Partners LLC (5.24%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Albert Friedberg, Jacob B Frieberg, Maurice Zauderer and Strydonck Gerald E Van.
View institutional ownership trends
.

How do I buy shares of Vaccinex?

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VCNX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners